Germany to Produce Maryland Created COVID-19 Vaccine
Illinois-based Baxter International Inc. announced that Baxter BioPharma Solutions has agreed to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M™ adjuvant.
The agreement with Maryland-based Novavax is expected to advance commercial-scale manufacturing essential for the vaccine’s production and distribution in the United Kingdom and European markets. Baxter’s manufacturing services for this experimental vaccine will take place at its facility in Halle/Westfalen, Germany.
“Our priority is to bring a safe, effective COVID-19 vaccine to people around the world,” said Rick Crowley, Novavax's EVP and COO, in a press statement issued on January 11, 2021.